NEW YORK -The chief executive of Amgen Inc. sought to reassure investors Monday that the company will overcome a variety of difficulties with regulators on its anemia drugs that have threatened to curb their use."We’re a company that obviously has more than our share of challenges right now,” Kevin Sharer told a group of analysts at conference in New York. “We have a new reality in the business and its not a completely predictable dynamic.”
